Toremifene

This MedLibrary.org supplementary page on Toremifene is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Related Sponsors

BM Pharmacy Generic pharmaceuticals at unbeatable prices. Insomnia, men's health, hair health, pain control. bmpharmacy.com
Online Pharmacy Carisoprodol, tadalafil, sildenafil, vardenafil and more... xlpharmacy.com
MedBasket.com Discreet. Inexpensive. Fast shipping. Great selection. What more can we say? medbasket.com
Frugalmed 2000 reasons to shop with us first. frugalmed.com
Ads by Tiva

Toremifene
Systematic (IUPAC) name
2-[4-(4-chloro-1, 2-diphenyl-but-1-enyl)phenoxy]- N,N-dimethyl-ethanamine
Identifiers
CAS number 89778-26-7
ATC code L02BA02
PubChem 3005573
DrugBank APRD00391
Chemical data
Formula C26H28ClNO 
Mol. mass 405.959 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding more than 99.5%
Metabolism  ?
Half life 5 days
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.[1]

GTx Inc. is currently conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008[2]

References

  1. ^ Price N, Sartor O, Hutson T, Mariani S. Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. Clin Prostate Cancer 2005;3:211-4. PMID 15882476
  2. ^ GTx Inc. (2007-07-12). "GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review". Press release. Retrieved on 2006-07-14.
v • d • e
Sex hormones and related agents (primarily G03, also L02, H01C) - human endogenous in CAPS
Progestogens:
(receptor)
Agonist
Antiprogestogen
Androgens:
(receptor)
Agonist
Estrogens:
(receptor)
Agonist
Antiestrogen
Gonadotropins:
(FSHR/LHCGR)
ovulation stim.
Antigonadotropin
GnRH:
(receptor)
Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Wikipedia content modification information:

  • This page was last modified on 18 September 2007, at 17:56.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Toremifene".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.